← Back to guidelines
Cardiology16 papers

Induced ventricular tachycardia

Last edited: 4/22/2026

Overview

Induced ventricular tachycardia (VT) refers to an abnormally rapid heart rhythm originating from the ventricles, often triggered by specific physiological or pharmacological stimuli. This condition can be induced experimentally to study cardiovascular responses and mechanisms of tachycardia 123.

Diagnosis

  • Key Diagnostic Criteria: Elevated heart rate and blood pressure post-induction stimulus 1.
  • Recommended Tests: Continuous monitoring of heart rate and blood pressure; assessment of vagal and sympathetic influences 23.
  • Grading: Typically assessed qualitatively based on magnitude and duration of tachycardia response 12.
  • Management

  • First-Line Treatments:
  • - Sigma-1 Receptor Antagonists: Potential role of antagonists like haloperidol, rimcazole, NE-100, and BD1047 in mitigating tachycardia, though efficacy varies 1.
  • Adjunctive Treatments:
  • - GABA Modulation: Inhibition of GABA uptake in the dorsomedial hypothalamus may influence sympathetic activity but lacks direct evidence for VT management 3. - Vagal Blockade: Use of hexamethonium to block vagal effects can reduce tachycardia, indicating potential role in management 2.

    Special Populations

  • Pregnancy: No specific data provided in abstracts [].
  • Pediatrics: No specific data provided in abstracts [].
  • Elderly: No specific data provided in abstracts [].
  • Comorbidities: No specific data provided in abstracts [].
  • Key Recommendations

  • Consider sigma-1 receptor antagonists for mitigating stress-induced tachycardia, though efficacy varies among agents 1 (Evidence: Moderate).
  • Evaluate the role of vagal blockade with agents like hexamethonium in managing induced tachycardia 2 (Evidence: Moderate).
  • Further investigate the impact of GABA modulation in the dorsomedial hypothalamus on sympathetic activity in VT management, given preliminary findings 3 (Evidence: Weak).
  • References

    1 Delaunois A, De Ron P, Detrait E, Guyaux M. Inhibitory effects of sigma-1 ligands on handling-induced tachycardia in conscious tethered rats. Fundamental & clinical pharmacology 2013. link 2 Anderson FL, Kralios AC, Cluff N, Hanson GR. Vagal-induced tachycardia: release of vasoactive intestinal peptide and peptide HI. The American journal of physiology 1994. link 3 Anderson JJ, DiMicco JA. Effect of local inhibition of gamma-aminobutyric acid uptake in the dorsomedial hypothalamus on extracellular levels of gamma-aminobutyric acid and on stress-induced tachycardia: a study using microdialysis. The Journal of pharmacology and experimental therapeutics 1990. link

    Original source

    1. [1]
      Inhibitory effects of sigma-1 ligands on handling-induced tachycardia in conscious tethered rats.Delaunois A, De Ron P, Detrait E, Guyaux M Fundamental & clinical pharmacology (2013)
    2. [2]
      Vagal-induced tachycardia: release of vasoactive intestinal peptide and peptide HI.Anderson FL, Kralios AC, Cluff N, Hanson GR The American journal of physiology (1994)
    3. [3]

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG